Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations
Notice Number:
NOT-MD-22-012

Key Dates

Release Date:

July 11, 2022

First Available Due Date:
August 08, 2022
Expiration Date:
August 08, 2025

Related Announcements

NOT-MD-19-001 - Notice of Special Interest in Research on the Health of Sexual and Gender Minority (SGM) Populations

PAR-19-276 - Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

PA-20-187 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)

PA-20-188 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)

PA-20-176 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)

PA-20-190 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)

PA-20-197 - Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)

PA-20-199 - Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Not Allowed)

PA-20-203 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)

PA-20-205 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)

PA-20-206 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)

PAR-20-154 - Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

RFA-DC-20-002 - Otolaryngology Residency Mentored Research Pathway (R25 Clinical Trial Not Allowed)

RFA-HG-20-036 - Advancing Genomic Medicine Research (R01 Clinical Trial Optional)

RFA-HG-20-037 - Advancing Genomic Medicine Research (R21 Clinical Trial Optional)

PAR-21-063 - NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)

PAR-21-064 - NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)

PAR-21-085 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)

PAR-21-086 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials)

PAR-21-087 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)

PAR-21-094 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)

PAR-21-095 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)

PAR-21-096 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)

PAR-21-107 - NIDCD Early Career Research (ECR) Award (R21 Clinical Trial Optional)

PAR-21-143 - NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00)

PAR-21-240 - Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)

PAR-21-241 - NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)

PAR-21-243 - Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)

RFA-HG-21-041 - New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional)

PAR-22-025 - NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)

RFA-DC-22-001 - NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01 Clinical Trial Optional)

RFA-DC-23-001 - NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)

Issued by

National Institute on Minority Health and Health Disparities (NIMHD)

National Human Genome Research Institute (NHGRI)

National Institute on Aging (NIA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute of Nursing Research (NINR)

National Center for Complementary and Integrative Health (NCCIH)

National Cancer Institute (NCI)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

Office of Research on Women's Health (ORWH)

Sexual and Gender Minority Research Office (SGMRO)

Purpose

This Notice is a reissue of and supersedes NOT-MD-19-001 - Notice of Special Interest in Research on the Health of Sexual and Gender Minority (SGM) Populations which calls for research on the health of sexual and gender minority populations. SGM populations include, but are not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex.

Although there has been an increase in SGM-focused health research in recent years, there remains a need for further research on the health of these populations. This Notice encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations.

Types of research which are relevant to this Notice include, but are not limited to:

  • Epidemiological research that examines patterns of risk, morbidity and mortality related to diseases or health conditions that have not been adequately studied in SGM populations.
  • Etiological or mechanistic research examining how biological, behavioral, social, and/or environmental factors contribute to health outcomes and health disparities for SGM populations.
  • Research leading to interventions to ameliorate health disparities in SGM populations, including formative research to identify and develop appropriate intervention content as well as pilot testing of interventions to establish feasibility, acceptability, and preliminary efficacy.
  • Large-scale design, implementation and evaluation of preventive and/or treatment interventions addressing health issues in SGM populations.

ICO Specific Application and Submission Information

NIH ICs have separately advanced funding opportunity announcements (FOAs) relevant to this NOSI. These FOAs might be specific to each IC mission area. Applicants must select the IC and associated FOA to use for submission of an application in response to the NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that FOA. Non-responsive applications will be withdrawn from consideration for this initiative. In addition, applicants using NIH Parent Announcements (listed below) will be assigned to those ICs on this NOSI that have indicated those FOAs are acceptable and based on usual application-IC assignment practices.

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed.

Investigators are strongly encouraged to reach out to the relevant contacts as listed below to identify which FOAs may be most appropriate for their proposed project or application.

Applicants must indicate the Notice number (NOT-MD-22-012) in the Agency Routing Identifier Field (box 4B) on the SF 424 application form and refer to NOT-MD-22-012 in the abstract to assist in identifying applications submitted to this Notice.

NIMHD areas of programmatic interest include but are not limited to:

  • Observational studies on how social determinants, such as minority stress, stigma and discrimination, lack of access to culturally competent healthcare, social networks, and social support, may cause, sustain, or ameliorate health disparities.
  • Epidemiological studies on the relationship between intersectionality of SGM status with other health disparity population membership and health outcomes. In addition to SGM populations, NIH-designated health disparity populations include racial/ethnic minorities, socioeconomically disadvantaged populations, and underserved rural populations.
  • Intervention studies in community and healthcare settings to reduce health disparities.

NIMHD encourages projects to use approaches that encompass multiple domains (e.g., biological, behavioral, socio-cultural, environmental, physical environment, health system) and multiple levels (e.g., individual, interpersonal, community, societal) to understand and address health disparities in SGM populations (see the NIMHD Research Framework, https://www.nimhd.nih.gov/about/overview/research-framework.html, for examples of health determinants of interest). Animal studies and studies focused on SGM populations outside of the US are not priorities for NIMHD under this Notice.

NCCIH is interested in supporting research on the use of complementary and integrative health approaches, including natural products and mind and body interventions, to manage stress, chronic pain, mild anxiety, or depression among SGM populations. NCCIH is also interested in research studying mind and body approaches to improve adherence to treatment (e.g., Medication Assisted Treatment (MAT) for opioid misuse, Antiretroviral therapy (ART) for HIV) and prevention (e.g., Pre-exposure prophylaxis (PrEP) for HIV) regimens to promote health outcomes. Natural products include botanicals, pre/probiotics, and products marketed as dietary supplements. Mind and body approaches include various meditation approaches (e.g., mindfulness), hypnosis or guided imagery, meditative movement approaches (e.g., yoga, tai chi, qi-gong), body-based approaches (e.g., spinal manipulation, massage, mobilization, acupuncture), a combination of these approaches (e.g., meditation and yoga, such as in mindfulness-based stress reduction MBSR), or complex interventions including music and art therapy. NCCIH offers a range of funding opportunity announcements to support clinical trials of natural products and mind and body interventions. Applicants are strongly encouraged to consult with the NCCIH Scientific Research contact prior to developing and submitting an application.

NCI areas of programmatic interest include (but are not limited to) studies that:

  • Identify cancer health care needs across the cancer continuum, including prevention, early detection, diagnosis, treatment, survivorship, and end of life care among SGM populations;
  • Increase understanding about the cancer care needs, health outcomes and effective interventions to improve outcomes for SGM individuals;
  • Assess cancer risk to inform improved decision-making, risk reduction interventions, and screening options for early cancer detection in SGM populations;
  • Evaluate interventions that increase rates of screening, follow-up, referral-to-care, and improve symptom management for cancer prevention and control among SGM populations;
  • Increase understanding of the barriers to cancer health care information and treatment that may lead SGM individuals/populations to avoid or delay seeking health care;
  • Examine the relative risk of cancer and cancer risk factors (e.g., smoking, obesity, aging, infections such as HPV or HIV, tobacco use, alcohol consumption, nulliparity) and underlying mechanisms of risk (social, behavioral, biological, clinical) in SGM groups in comparison to their heterosexual counterparts;
  • Investigate cancer patient outcomes, cancer treatment delivery, and healthcare utilization in SGMs;
  • Improve the understanding of the differential risks for certain types of cancers including cervical, breast, ovarian, anal, and other malignancies among SGMs;
  • Examine the potential cancer risks of hormone therapy (including off-label use) among transgender and/or intersex individuals;
  • Investigate prevalence rates of HPV infection in SGM groups and the development of screening interventions and/or recommendations to ameliorate HPV-associated disease;
  • Examine the intersection of contextual factors (e.g., race, geography, socioeconomic status) on cancer health outcomes across SGM groups;
  • Investigate the lack of access to and utilization of cancer health care services, and quality of care received, by SGM populations and impact on health outcomes;
  • Assess the impact of stigma, discrimination, victimization, substance use, and other risk factors on utilization of cancer preventive screening/services;
  • Investigate positive and/or protective factors (e.g., family and/or social support) on cancer prevention.
  • Explore the effects of policy and legislative efforts to restrict comprehensive sex education and gender-affirming health care on the health and well-being of queer youth.

NHGRI supports the development of resources, approaches, and technologies that accelerate and support studies focused on the structure and biology of genomes; the genomics of disease; the implementation and effectiveness of genomic medicine; genomic data science and bioinformatics; and ethical, legal, and social issues related to genomic advances. More details about the institute’s vision and priority areas can be found in the 2020 NHGRI Strategic Vision (https://www.genome.gov/2020SV).

Areas of programmatic interest to NHGRI include but are not limited to:

  • Development of resources, approaches, and technologies that will accelerate genomic research on the structure of genomes, the biology of genomes, and the biology of disease;
  • Developments that will use genomics to advance the science of medicine, and that will incorporate genomics to improve the effectiveness of healthcare;
  • Research in several cross-cutting areas, including:
    • Health equity implications of genomic research
    • Ethical, legal and societal implications of genomics research
    • Bioinformatics and data science
    • Research training and career development, including genomic workforce diversity.

NHGRI strongly encourages investigators that plan to collect phenotype and/or environmental exposure data about their study participants to utilize standard protocols included in the PhenX Toolkit (http://www.phenxtoolkit.org).

NIA is interested in research that can improve the understanding of aging processes and experiences that impact health and well-being in middle-aged and older SGM adults, and studies that use a life-course approach to examine how early life exposures contribute to SGM health disparities in adulthood. NIA welcomes multilevel research focused on the level of the individual, dyad, family, population, and/or system, and the use of multidimensional components of sexual orientation (identity, attraction, and behavior) and gender identity. For studies with participants in the United States, NIA strongly encourages researchers to use measures for the concepts of sex, gender identity, and sexual orientation and the guiding principles for data collection outlined in the NIH-commissioned National Academies’Consensus Study Report Measuring Sex, Gender Identity, and Sexual Orientation (2022).

NIA is especially interested in aging-relevant SGM research with communities that are currently underrepresented in aging and clinical research; in particular, people who identify as transgender or intersex and/or people with differences of sex development (DSD), and members of other NIA-designated priority populations, as specified in the NIA Health Disparities Research Framework.

NIA is interested in interventions that are mechanism based and guided by the NIH Stage Model framework and applicants are encouraged to follow the experimental medicine approach to intervention development promoted by the NIH Science of Behavior Change. Studies focused on health equity and health disparities are expected to be guided by the NIA Health Disparities Research Framework. NIA encourages SGM research focused on Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD). Areas of AD/ADRD research emphasis include, but are not limited to, those described in NIA’s AD+ADRD Research Implementation Milestones.

NIA supports cross-national studies to better understand the aging experience on a global level and the effects of various policies. “Natural experiments”, arising from policy change or regional differences, may provide another powerful approach for examining mechanisms affecting the health of SGM older adults. Applicants are encouraged to leverage NIA’s investment in data infrastructure and publicly available datasets, including but not limited to: the Health and Retirement Study (HRS) and HRS’s International Sister Studies, Midlife in the United States (MIDUS), National Social Life, Health, and Aging Project (NSHAP), National Longitudinal Study of Adolescent to Adult Health (Add Health), Study of Women's Health Across the Nation (SWAN), and the Aging with Pride: National Health, Aging, and Sexuality/Gender Study (NHAS). Applicants are encouraged to consult with the NIA’s Office of Data Resources and Analytics (ODRA) for guidance on the use of data in NIA’s infrastructure projects.

Areas of programmatic interest to NIA include but are not limited to:

  • Studies examining interpersonal processes, and the situational contexts that influence them and lead to positive and healthy relationships in adulthood and older age. NIA is especially interested in research that can identify mechanisms that underlie associations between marital status, long-term romantic partnerships, and health.
  • Studies examining how factors such as social identity, intersectionality, positionality, and stigma impact well-being, and health in later life.
  • Causes and consequences of self-disclosing sexual orientation and gender identity in mid-late life and older age to families, intimate partners, employers, health care practitioners, and institutions.
  • Studies of unique caregiving needs of older SGM individuals, especially, for individuals with Alzheimer’s disease and related dementias and their families (of origin and chosen).
  • Research that can improve the understanding of the unique needs of SGM patients and lead to the development of behavioral interventions to improve health care utilization and access and enhance communication in health care settings
  • Development of nationally representative data infrastructure to support cohort studies of older SGM adults, including intersectional research with NIA-designated priority populations, as specified in the NIA Health Disparities Research Framework. NIA is also interested in research that can lead to the development of recruitment strategies to improve the representation of older participants from SGM groups that are currently underrepresented in aging and clinical research.

NIAID areas of programmatic interest include but are not limited to:

  • Research on all areas of HIV infection, including developing and testing preventive HIV vaccines, and other prevention strategies, and new treatments for HIV infection and AIDS-associated opportunistic infections
  • Basic and applied research to better understand, treat, and ultimately prevent other infectious, immunologic, and allergic diseases.
  • .

NIAMS has the mission to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. NIAMS also conducts and supports basic research on the normal structure and function of bones, joints, muscles, and skin. Basic research involves a wide variety of scientific disciplines, including immunology, genetics, molecular biology, structural biology, biochemistry, physiology, virology, and pharmacology. Clinical research areas include rheumatology, orthopaedics, dermatology, metabolic bone diseases, heritable disorders of bone and cartilage, inherited and inflammatory muscle diseases, and sports and rehabilitation medicine. NIAMS also seeks studies that include sufficient numbers of SGM individuals to enable robust sub-group analyses. Clinical trials designed to answer specific questions about the safety, tolerability, efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions will only be supported by NIAMS if submitted to a NIAMS clinical trials-specific FOA. A current list of active NIAMS clinical trials FOAs is available at https://www.niams.nih.gov/grants-funding/conducting-clinical-research/grants. For information regarding NIAMS supported scientific areas/programs and contacts, please see: https://www.niams.nih.gov/grants-funding/supported-scientific-areas.

NICHD mission is to lead research and training to understand human development, improve reproductive health, enhance the lives of children and adolescents, and optimize abilities for all. NICHD's broad and diverse research portfolio includes research related to conception and pregnancy; typical and atypical development in childhood; childhood trauma, injury, and critical illness; the transition from adolescence to adulthood; reproductive health; rehabilitation; intellectual, developmental, and physical disabilities; and population dynamics across the lifespan.

For this NOSI, NICHD seeks applications addressing issues in SGM health that are aligned with NICHD scientific priorities. NICHD high priority populations include children and adolescents, pregnant and lactating people, and people of all ages with physical and/or intellectual disabilities. Areas of interest include, but are not limited to:

  • Research on health disparities between SGM youth and/or young adults and their heterosexual and/or cisgender peers, including:
    • Risk and protective factors that mediate or moderate health disparities
    • Demographic, economic, and social characteristics that may affect health, development, and access to care
    • Individual, relational, and structural factors related to disparities in gynecological, reproductive, and pregnancy-related outcomes and care
    • Impact of bullying and teen dating violence on social, emotional, and psychological development
    • Inclusion of SGM populations in large-scale population-representative surveys, especially longitudinal studies, to improve studies of health disparities
  • Design, implementation, and/or evaluation of interventions for SGM populations, including interventions to:
    • Reduce inequities in and improve sexual and reproductive healthcare and outcomes
    • Reduce the prevalence and impact of bullying and dating violence affecting SGM youth and young adults
    • Address the effectiveness of violence-related screening, prevention, treatment, and/or case management for SGM youth and adolescents along with appropriate referrals and linkages to services, resources, and support within the community
  • Development and validation of measures, instruments, and/or methods to improve research on SGM populations, including:
    • Measures of sexual orientation and gender identity for use among youth populations and/or among persons with disabilities
    • Measures or methods to capture changes in sexual orientation and gender identity over time, especially during the transition from adolescence to adulthood
    • Methods for estimating the size and characteristics of small, hard-to-reach populations
    • Measures or methods to capture the effects of intersectionality with other NIH-designated health disparities populations and/or disability status
  • Studies among SGM youth and/or young adult populations that examine the effects of hormonal and surgical therapies, including how they are mediated or moderated by timing and/or duration, on:
    • Obesity, growth, endocrine function, musculoskeletal health, and pubertal maturation
    • Gynecological outcomes, reproductive function, fertility options, fertility preservation, and gamete quality
    • Differences in pharmacokinetic and/or pharmacodynamic properties of medications
    • Socioemotional outcomes, brain development and function, and cognition
  • Research on clinical care for SGM children, adolescents, and young adults, including:
    • Service provision in pediatric primary and/or emergency care
    • Access to and use of trauma-informed care among youth and young adults exposed to violence

NIDCD welcomes responsive applications involving SGM populations with communication disorders including those affecting hearing, balance, taste, smell, voice, speech, and language. In particular, research to identify and reduce health care disparities and inequities in the SGM population in the areas of NIDCD’s scientific mission are encouraged. NIDCD also encourages applications focused on research on gender affirming intervention to facilitate congruence between an individual’s voice and/or other aspects of their communication and their gender identity and/or gender expression. Research to improve the evidence base for voice intervention with SGM populations is also highly encouraged.

NIDCR areas of programmatic interest include but are not limited to:

  • Observational studies identifying how social determinants of oral health contribute to or ameliorate oral health disparities in SGM individuals or populations. Examples of social determinants include minority stress, stigma and discrimination, lack of access to oral care, cross-cultural awareness, social networks, and social support.
  • Observational studies exploring the relationship between intersectionality of SGM status with other health disparity population membership and oral health disparities. In addition to SGM populations, NIH-designated health disparity populations include racial/ethnic minorities, socioeconomically disadvantaged populations, and underserved rural populations.
  • Epidemiologic research on the prevalence and unmet dental, oral, and/or craniofacial needs of SGM individuals, e.g., oral cancers, oral complications of HIV/AIDS, orofacial trauma.
  • Studies developing interventions to reduce oral health disparities for SGM individuals or populations, targeting individual, family, community, provider, health system, and/or policy levers of change.
  • Research on craniofacial skeletal tissue homeostasis, injury, and repair in the presence of hormone therapy.

NIDDK supports medical research and research training and dissemination of science-based information on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases, to improve people’s health and quality of life. NIDDK Encourages Research on Sex/Gender Differences, Sexual and Gender Minority-Related Research and Race/Ethnic Diversity as defined in NOT-DK-22-003 (https://grants.nih.gov/grants/guide/notice-files/NOT-DK-22-003.html). More specifically, NIDDK encourages investigators to consider research on differences in health status across biological and social constructs of identity. The potential implications of these concepts should be considered in research across multiple levels, from genes to hormones, to complex biological systems, to social and ecological interactions. Assessing the contributions of these biological and social constructs of identity can assist in understanding variations in health outcomes among SGM populations, across NIDDK research mission areas.

NIDA areas of programmatic interest include but are not limited to:

  • Innovative drug abuse epidemiology, prevention, and health services research among SGM populations;
  • Translational research that applies findings from epidemiology, cognitive science, neuroscience, and other sciences to develop and test novel prevention interventions among SGM populations;
  • Treatment development research and testing for substance use disorders, including behavioral treatments, among SGM populations;
  • Vulnerability to addiction and biological etiology among SGM populations;
  • Behavioral and cognitive mechanisms and consequences of substance or polysubstance use among SGM populations.

NIEHS areas of programmatic interest include but are not limited to:

  • Studies to better understand the impact of environmental exposures, such as endocrine disrupting chemicals, on gonadal development and other hormonal systems that affect sexual development
  • Development of resources, approaches, and technologies that will promote research on environmental conditions that effect the health of sexual and gender minority populations

NINDS is interested in mission relevant applications. In addition to the above topics, NINDS is interested in funding applications that enrich scientific understanding of how sexual orientation, gender identity, and/or being born with differences/disorders in sex development (DSDs) or intersex characteristics relate to health outcomes, health risks, health behaviors, perceptions and expectations about health, and access to health-related services or associated barriers as they pertain to the NINDS mission. The NINDS supports basic, clinical, translational, and implementation research focused on identifying, monitoring, and targeting biological, environmental, social, community, structural, and healthcare system factors that lead to or are associated disparities (or inequities) in neurological diseases and care across the lifespan. Some priority disease areas include stroke and other cerebrovascular diseases, Alzheimer’s disease-related dementias (including frontotemporal neurodegeneration, Lewy body dementias, vascular contributions to cognitive impairment and dementia and mixed etiology dementia), epilepsy, migraine, nervous system infections, spinal cord injury, headache, Parkinson's disease, and other neurodegenerative disorders, brain trauma, neurodevelopmental disorders, and the neurological consequences of HIV/AIDS. Observational studies should be theory-based to enable the future development of actionable items and evidence-based interventions. Applicants are encouraged to incorporate community engagement strategies into their study designs. A letter of intent and communication with NINDS program staff prior to submission of an application is strongly encouraged. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program.

For PA-20-183, only mechanistic clinical trials will be accepted in accordance with NOT-NS-18-011. Applicants wishing to propose other clinical trials (i.e., efficacy, effectiveness, feasibility, acceptability, and implementation) through separate FOAs should consider reviewing submission guidelines listed on the NINDS clinical trials website. A letter of intent and communication with NINDS program staff prior to submission of an application is strongly encouraged

NINR supports research to solve pressing health challenges and inform practice and policy - optimizing health and advancing health equity into the future. NINR discovers solutions to health challenges through the lenses of health equity, social determinants of health, population and community health, prevention and health promotion, and systems and models of care. Drawing on the strengths of nursing’s holistic, contextualized perspective, core values, and broad reach, NINR funds multilevel and cross-sectoral research that examines the factors that impact health across the many settings in which nurses work, including homes, schools, workplaces, clinics, justice settings, and the community. Observational, intervention, and implementation research are of interest.

Areas of programmatic interest to NINR include but are not limited to

ORWH is interested in projects of relevance to the health of SGM women and individuals assigned female at birth, especially projects that consider sex and/or gender in intersection with other social determinants of health. Specific areas of interest include, but are not limited to,:

  • Gender-transformative, culturally-competent, and community-engaged interventions to improve health outcomes for SGM women and individuals assigned female at birth;
  • Projects using data science, mHealth, and other innovative approaches to address health inequities experienced by SGM women and individuals assigned female at birth;
  • SGM disparities in cancer-related risk behaviors;
  • Female-specific conditions in SGM populations, including issues relating to healthcare access, health literacy, and provider awareness of SGM considerations;
  • Co-morbidities and multi-morbidity in SGM populations;
  • Interventions to support sensitive approaches to SOGI data collection for diverse populations of women and SGM individuals;
  • Caregiving, including caregiver strain and mental health outcomes, in SGM communities;
  • Role of community support in health behaviors, access, and outcomes for SGM women and individuals assigned female at birth;
  • Implementation projects to improve healthcare access and outcomes for SGM women and individuals assigned female at birth;
  • Projects, including observational studies, to identify and address unique health needs of SGM populations through the menopausal transition;
  • Other projects aligned with the 2019-2023 NIH-Wide Strategic Plan for Women’s Health Research

Application and Submission Information

This notice applies to due dates on or after August 1, 2022 and subsequent receipt dates through August 1, 2025.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

Activity Code

FOA

First Available Date

Participating ICs

R03

PAR-19-276 - Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

October 16, 2022

NINDS

R01

PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)

October 5, 2022

NHGRI, NIA, NIAID, NICHD, NIAMS, NIDDK, NIDA, NIEHS, NIGMS, NINDS, NIMHD, NCCIH

R01

PA-20-184 - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

October 5, 2022

NIA, NIAAA, NICHD, NIDCR, NIDDK, NIDA, NIEHS, NIMH, NINDS, NIMHD, NCCIH

R01

PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

October 5, 2022

NHGRI, NIA, NIAID, NIAMS, NICHD, NIDCD, NIDCR, NIDDK, NIDA, NIEHS, NINDS, NIMHD, NCCIH, NCI

K99/R00

PA-20-187 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)

October 12, 2022

NCI, NHGRI, NIA, NIAMS, NICHD, NIDA, NCCIH, NIDCD, NIDCR, NIDDK, NIEHS, NIMHD

K99/R00

PA-20-188 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)

October 12, 2022

NCI, NHGRI, NIA, NIAMS, NIAID, NCCIH, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIMHD

K01

PA-20-176 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)

October 12, 2022

NHGRI, NIA, NIAMS, NICHD, NIDA, NCCIH, NIDCD, NIDCR, NIMHD

K01

PA-20-190 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)

October 12, 2022

NHGRI, NIA, NIAMS, NICHD, NIDA, NCCIH, NIDCD, NIDCR, NIMHD, NIAID, NIDDK

K25

PA-20-197 - Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)

October 12, 2022

NHGRI, NIA, NICHD, NIDCD, NIDCR, NIDDK, NIDA, NIEHS, NCI

K25

PA-20-199 - Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Not Allowed)

October 12, 2022

NIA, NIAID, NIAMS, NICHD, NIDCD, NIDCR, NIDA, NIDDK, NIEHS, NCI, NHGRI

K08

PA-20-203 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)

October 12, 2022

NCI, NHGRI, NIA, NIAID,

NIAMS, NICHD, NIDCD, NIDCR, NIDDK, NIDA, NIEHS, NCCIH, NIMHD

K23

PA-20-205 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)

October 12, 2022

NIA, NIAMS, NIAID, NICHD, NIDCD, NIDCR, NIDDK, NIDA, NIEHS, NIGMS, NINR, NIMHD

K23

PA-20-206 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)

October 12, 2022

NIA, NIAMS, NICHD, NIDCD NIDCR, NIEHS, NIDDK, NIDA, NCCIH, NIMHD

R01

PAR-20-154 - Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

October 5, 2022

NCCIH

R25

RFA-DC-20-002 - Otolaryngology Residency Mentored Research Pathway (R25 Clinical Trial Not Allowed)

October 11, 2022

NIDCD

R01

RFA-HG-20-036, Advancing Genomic Medicine Research (R01 Clinical Trial Optional)

August 1, 2022

NHGRI

R21

RFA-HG-20-037, Advancing Genomic Medicine Research (R21 Clinical Trial Optional)

August 1, 2022

NHGRI

R01

PAR-21-063 - NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)

October 5, 2022

NIDCD

U01

PAR-21-064 - NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)

October 11, 2022

NIDCD

K01

PAR-21-085 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)

October 13, 2022

NIDCD

K01

PAR-21-086 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials)

October 13, 2022

NIDCD

K01

PAR-21-087 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)

October 13, 2022

NIDCD

K18

PAR-21-094 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)

October 7, 2022

NIDCD

K18

PAR-21-095 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)

October 7, 2022

NIDCD

K18

PAR-21-096 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)

October 7, 2022

NIDCD

R21

PAR-21-107 - NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)

October 27, 2022

NIDCD

F99/K00

PAR-21-143, NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00)

August 8, 2022

NHGRI

R34

PAR-21-240 - Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)

October 19, 2022

NCCIH

R01

PAR-21-241 - NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)

October 19, 2022

NCCIH

U3/UH3

PAR-21-243 - Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)

October 19, 2022

NCCIH

R01

RFA-HG-21-041, New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional)

February 22, 2023

NHGRI

P50

PAR-22-025 - NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)

October 6, 2022

NIDCD

R01

RFA-DC-22-001 - NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01 Clinical Trial Optional)

February 22, 2023

NIDCD

R01

RFA-DC-23-001 - NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)

August 5, 2022

NIDCD

Application and Submission Information

This notice applies to due dates on or after August 8, 2022 and subsequent receipt dates through September 8, 2022. 

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

  • PA-19-055 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
  • PA-19-056  - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-19-091 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include “NOT-MD-22-012” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

Inquiries

Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.

Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements. 

Crystal L. Barksdale, PhD MPH
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-827-4228
Email: crystal.barksdale@nih.gov